knowledge -WSS

knowledge

author：leisure time 2025-09-29 10:31:27 - browse：71819

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： NIH documents show early flaws of $1.6 billion long Covid program

leisure time

WSS

Doctors are clamoring for more clarity on Paxlovid prescribing

NFL doctors' conflicts of interest could endanger players, report says

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Trump used to be more articulate. What could explain the change?

BMI, flaws aside, is found to be useful estimate of body fat in youth

Kaiser's Risant Health gobbled up Geisinger. Who is next?

hotspot

knowledge

entertainment

Jerome Adams on the need for new antivirals for Covid

McConnell is warmly embraced by Kentucky Republicans amid questions about his health

Hollywood unions extend contract negotiations for actors

It was time to plan for my old age. If only I could stop crying

In age of alternative facts, a scholarly course on calling out crap

How to increase colonoscopy rates? Looks like an AI can help

Wildfire smoke exposes gaps in outdoor worker protections

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

Medical leaders decry Supreme Court decision on affirmative action

How CRISPR works, explained in two minutes

explore

Trump used to be more articulate. What could explain the change?

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Google's generative AI to analyze medical images — and talk to docs

Judge in Trump's classified documents case questions use of out

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

leisure time

focus

hotspot

hotspot